PROCEPT BioRobotics (NASDAQ:PRCT) Reaches New 52-Week Low After Analyst Downgrade

PROCEPT BioRobotics Corporation (NASDAQ:PRCT)’s share price reached a new 52-week low during trading on Wednesday after TD Cowen lowered their price target on the stock from $85.00 to $50.00. TD Cowen currently has a buy rating on the stock. PROCEPT BioRobotics traded as low as $31.72 and last traded at $32.5210, with a volume of 1295291 shares. The stock had previously closed at $35.02.

Several other research firms have also recently issued reports on PRCT. Piper Sandler reiterated an “overweight” rating and set a $50.00 price objective (down from $55.00) on shares of PROCEPT BioRobotics in a report on Wednesday. Wall Street Zen raised shares of PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Leerink Partners restated an “outperform” rating and set a $55.00 price objective on shares of PROCEPT BioRobotics in a report on Wednesday. Stephens began coverage on PROCEPT BioRobotics in a research report on Wednesday, July 9th. They issued an “overweight” rating and a $70.00 target price on the stock. Finally, Oppenheimer raised PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 price target for the company in a research report on Tuesday, September 2nd. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $63.30.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of PRCT. ANTIPODES PARTNERS Ltd acquired a new position in shares of PROCEPT BioRobotics in the 1st quarter valued at $30,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of PROCEPT BioRobotics during the 1st quarter valued at about $40,000. Vega Investment Solutions grew its position in PROCEPT BioRobotics by 52.0% in the second quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after acquiring an additional 265 shares in the last quarter. JTC Employer Solutions Trustee Ltd acquired a new position in PROCEPT BioRobotics during the third quarter worth $30,000. Finally, CWM LLC raised its stake in shares of PROCEPT BioRobotics by 69.5% in the 1st quarter. CWM LLC now owns 873 shares of the company’s stock valued at $51,000 after acquiring an additional 358 shares in the last quarter. 89.46% of the stock is owned by institutional investors and hedge funds.

PROCEPT BioRobotics Stock Up 2.0%

The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -20.86 and a beta of 0.98. The firm has a 50-day moving average of $36.02 and a two-hundred day moving average of $47.66. The company has a current ratio of 8.44, a quick ratio of 7.86 and a debt-to-equity ratio of 0.14.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.03. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The business had revenue of $83.33 million for the quarter, compared to analyst estimates of $80.78 million. During the same quarter in the prior year, the firm earned ($0.40) EPS. The firm’s quarterly revenue was up 42.6% compared to the same quarter last year. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts predict that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).